Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Viatris (0A5V) Share Price & Analysis

0 Followers

0A5V Stock Chart & Stats

$20.99$0.32(1.57%)
At close: 4:30 PM GMT
$16$18$20Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$20.52 - $21.11
52-Week Range
$10.15 - $21.11
Previous Close
$20.67
Volume
N/A
Average Volume (3M)
9,548
Market Cap
$23.90B
Enterprise Value
$32.03B
Total Cash (Recent Filing)
$1.90B
Total Debt (Recent Filing)
$13.58B
Price to Earnings (P/E)
―
Beta
0.88
Next Earnings
Mar 01, 2027 (Est.)
EPS Estimate
0.61
Next Dividend Ex-Date
N/A
Dividend Yield
2.28%

Bulls Say, Bears Say

Bulls Say

Strong Cash Generation

Consistently positive free cash flow provides Viatris with internally generated funding for debt service, dividends, reinvestment, and business development. This is particularly valuable because cash generation remains strong even while GAAP earnings are negative, supporting financial resilience over the next several quarters.

Higher-Margin Portfolio Growth

Growth in complex generics, injectables, respiratory medicines, and hormone patches can improve the mix beyond commoditized generics. The combination of strong demand and added patch capacity gives Viatris a more durable route to revenue and margin improvement in its U.S. business.

Pacira Strategic Expansion

The proposed Pacira acquisition would broaden Viatris into patent-protected, non-opioid pain medicines while adding commercial and development capabilities. If completed as planned, the transaction could strengthen the innovative portfolio, support revenue diversification, and provide identifiable cost synergies.

Bears Say

Persistent GAAP Losses

Ongoing GAAP losses and a multi-year revenue downtrend show that Viatris has not yet converted its operating platform into consistent bottom-line earnings. Although EBITDA and cash flow remain positive, continued losses can restrict balance-sheet flexibility and make long-term performance more dependent on execution.

Nashik Supply And Regulatory Disruption

The Nashik remediation creates a durable operational and regulatory overhang rather than a routine quarterly fluctuation. Manufacturing suspension has already affected Europe and emerging markets, and continued constraints could reduce product availability, pressure revenue, and require management resources until remediation is completed.

Product Exclusivity And Competition Pressure

Upcoming and recent loss-of-exclusivity events expose Viatris to generic competition and potential erosion in established-product revenue. This pressure is structurally important because it can offset pipeline launches and portfolio improvements, requiring continual replacement of products whose market protection is declining.

Viatris News

0A5V FAQ

What was Viatris’s price range in the past 12 months?
Viatris lowest share price was $10.15 and its highest was $21.11 in the past 12 months.
What is Viatris’s market cap?
Viatris’s market cap is $23.90B.
When is Viatris’s upcoming earnings report date?
Viatris’s next earnings report is estimated for Mar 01, 2027 (not yet confirmed), which is in 108 days.
How were Viatris’s earnings last quarter?
Viatris released its earnings results on Nov 05, 2026. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.637 by $0.073.
Is Viatris overvalued?
According to Wall Street analysts Viatris’s price is currently Overvalued.
Does Viatris pay dividends?
Viatris does not currently pay dividends.
What is Viatris’s EPS estimate?
Viatris’s EPS estimate is 0.61.
How many shares outstanding does Viatris have?
Viatris has 1,146,454,700 shares outstanding.
What happened to Viatris’s price movement after its last earnings report?
Viatris reported an EPS of $0.71 in its last earnings report, beating expectations of $0.637. Following the earnings report the stock price went down -0.315%.
Which hedge fund is a major shareholder of Viatris?
Hedge funds hold Viatris shares: the largest hedge-fund position in Viatris is 1,877,924,926 shares, and hedge funds decreased their holdings by 147.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology